stockportfolio.pro
Stocks / CHE vs PTCT
CHE vs PTCT
Chemed Corporation and PTC Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Chemed Corporation (CHE) | PTC Therapeutics, Inc. (PTCT) | |
|---|---|---|
| Market cap | $5.8B | $6.1B |
| Revenue (latest FY) | $2.53B | $1.73B |
| Net income (latest FY) | $265.24M | $682.64M |
| Revenue growth (5y CAGR) | 4.0% | 35.4% |
| Net margin | 10.5% | 39.4% |
| Return on equity | 27.1% | -332.5% |
| P/E ratio | 23.6 | — |
| Dividend yield | 0.5% | — |
| Profitable years (of last 10) | 10 | 1 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CHE — free Open PTCT — freeFrequently asked questions
Which is bigger, CHE or PTCT?
PTC Therapeutics, Inc. is larger by market capitalization — $6.1B versus $5.8B.
Which grows faster, CHE or PTCT?
Over the last five fiscal years, PTC Therapeutics, Inc. grew revenue faster — 35.4%/yr versus 4.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.